Anemia Treatment Differs in Lymphoma
Published: 2017-11-16 |
Author: James Nam, PharmD |
Source: Oncology Nurse Advisor
Patients with lymphoma who suffer from moderate to severe anemia may have better outcomes after 3 months receiving the same supportive treatment as patients with multiple myeloma, and only increases in hemoglobin levels were significantly associated with improvements in fatigue and health-related quality of life (HRQoL), a study published in Supportive Care in Cancer has shown.
Anemia is a common comorbidity that occurs in approximately 70% of patients with blood cancers and has a negative impact of HRQoL. The purpose of this study was to analyze the impact and effectiveness of supportive therapies in anemia based on patient-reported outcomes.
For this prospective, observational study, researchers assessed the outcomes of 250 patients with lymphoma. Patient perception of fatigue was assessed at baseline using PERFORM questionnaire, the Functional Assessment of Cancer Therapy-Fatigue subscale, the linear analogue self-assessment, and visual analogue scale (VAS), and assessed again at 3 months.
At baseline, 59.2% of patients with lymphoma received treatment for anemia, which consisted primarily of erythropoiesis-stimulating agents (ESAs). After 3 months, patients with lymphoma experienced a significant increase in hemoglobin levels.